SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.40-1.5%Dec 31 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (5202)12/21/2001 11:37:40 AM
From: Bob L  Read Replies (2) of 52153
 
Thanks, Peter.
"...with known CHD" seems like a fairly big caveat. Many people taking statins have not been diagnosed with CHD. They have been identified as at risk by cholesterol testing. So the statin-taking population may be different from the men with CHD population. Plus, the standard practice is to start with statin, which may raise HDL enough, in some people, that it is no longer considered low enough to be a significant risk.

I'm just being a bit of a devil's advocate here, suggesting the niacin-statin population may be significantly smaller than the statin population.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News